P2–298: Assessing the economic value of potential disease‐modifying agents in Alzheimer's disease using simulation

not available. P2-299 TENDENCIES OF TREATMENTAMONG PEOPLE WITH ALZHEIMER’S DISEASE IN MEXICO: FINDINGS FROM THE NATIONAL DEMENTIA SURVEY—STUDY FROM THE MEXICAN GROUP OF SPECIALISTS IN DEMENTIAS Santiago Ramirez Diaz, Carolina Gomez, Leonardo Barba, Guillermo Albert, Sarug Reyes, Jose Antonio Caldera, Juan Pablo Acero, Claudia Medina, Biomedical Research Institute, Aguascalientes, Mexico; Spanish Hospital, Mexico City, Mexico. Contact e-mail: ramirezdiazsp@gmail.com Table 3 Spearman correlation between costs and caregiver burden (Zarit in Total Score) for the total sample and stratified by severity of dementia among patients. Variables ZARIT (total score) Total sample Mild Moderate Severe Rho p-value Rho p-value Rho p-value Rho pvalue Indirect Costs Time/ Cost expensive with ADL h/day 0.14 0.309 0.40 0.046 -0.12 0.610 0.18 0.618 R$/day 0.14 0.309 0.40 0.046 -0.12 0.610 0.18 0.618 Days/month 0.08 0.578 0.41 0.044 -0.14 0.550 -0.51 0.130 Mean of the days spent pat/month. -0.00 0.991 -0.25 0.405 0.30 0.392 -0.76 0.046 Clothing 0.06 0.664 0.13 0.546 -0.45 0.047 0.50 0.140 R$/month 0.12 0.385 0.38 0.058 -0.12 0.610 0.10 0.781 Total h/month 0.11 0.405 0.38 0.060 -0.12 0.610 0.10 0.781 Time cost expense with IADL h/day 0.10 0.490 0.04 0.833 0.19 0.413 -0.06 0.865 R$/day 0.10 0.490 0.04 0.833 0.19 0.413 -0.06 0.865 Days/month 0.03 0.832 -0.11 0.584 0.15 0.541 -0.07 0.844 R$/month 0.15 0.279 0.14 0.498 0.23 0.337 0.01 0.980 Total h/month 0.15 0.278 0.14 0.494 0.23 0.337 0.01 0.980 Time cost expense with / supervision h/day 0.09 0.505 0.16 0.450 0.04 0.866 -0.31 0.381 R$/day 0.09 0.498 0.16 0.450 0.05 0.824 -0.31 0.381 Days/month -0.06 0.669 -0.27 0.195 0.36 0.117 -0.51 0.130 R$/month 0.02 0.898 -0.02 0.937 0.05 0.824 -0.37 0.294 Total h/month 0.02 0.906 -0.02 0.937 0.04 0.866 -0.37 0.294 Total Cost (patient month) 0.12 0.392 0.14 0.490 0.08 0.743 -0.37 0.333 Annual Cost (w / caregiver) 0.10 0.467 0.14 0.490 0.08 0.743 -0.35 0.321 Mean Time disp. Pac. / Month (h) -0.05 0.752 -0.03 0.922 -0.20 0.455 -0.51 0.160 Average days disp. Pac. / Month -0.00 0.991 -0.25 0.405 0.30 0.392 -0.76 0.046 Direct Costs Medication 0.01 0.915 0.00 0.989 0.07 0.764 -0.17 0.639 Consultation/ health insurance 0.01 0.963 -0.07 0.749 0.33 0.149 -0.45 0.188 Transport 0.08 0.586 0.05 0.800 -0.07 0.782 0.24 0.496 Feed -0.05 0.725 0.00 0.995 -0.09 0.695 -0.12 0.742 Diapers -0.02 0.880 – – -0.14 0.546 0.12 0.750 Clothing 0.06 0.664 0.13 0.546 -0.45 0.047 0.50 0.140 Other 0.02 0.893 0.06 0.767 0.11 0.648 -0.26 0.468 Caregiver Paid? (11⁄4yes; 21⁄4No) -0.03 0.838 -0.20 0.342 -0.13 0.574 0.21 0.553 Poster Presentations: P2 P468 Background: The Mexican group of specialists in dementia is a group of geriatricians, psychiatrists and neurologists dedicated to the diagnosis, Table 1 Distribution of patients with Alzheimer’s disease, according to whether or not they received drug therapy and type of medication Cognitive impairment therapy in patients with Alzheimer’s disease n % Total of patients with Alzheimer’s disease 560 100 Patients with treatment 479 85.54 Patients without treatment 81 14.46 Distribution of patients according to medication type n % Acetyl cholinesterase Inhibitors 219 45.72 Donepezil 66 13.78 Rivastigmine 104 21.71 Galantamine 49 10.23 Memantine 175 36.53 Combined therapy 85 17.75 Total of patients with treatment 479 100 teaching and research of dementia that bind in delphi consensus to help the prevention and treatment of dementia in mexico. We currently have several drug treatments for dementia, some of them are already listed in the guides of diverse groups and nations. However, there is great heterogeneity (neurologists, psychiatrists and geriatricians) in the correct choice of treatment of dementia. Methods: Starting from the National Dementia Survey, performed in specialized Alzheimer’s centers over 9 months. Data related with the treatment of the Alzheimer’s disease was collected. Recorded data included the use of cognitive impairment related (CIR) medication and non-cognitive related (NCIR) medication used on the patients as well as most common pharmaceutical combinations. Results: Thirty-four centers participated in the study. A total of 1350 patients were included, 41.48% (n1⁄4560) of the total were diagnosed with AD, 85.54% (n1⁄4479) of these patients received a CIR therapy from which 45.72% (n1⁄4219) received an Acetylcholinesterase inhibitor: 21.71% (n1⁄4104) received Rivastigmine, 13.78% (n1⁄466) received Donepezil and 10.23% (n1⁄436.53) received Galantamine; finally 36.53% (n1⁄4175) received Memantine. Combinations were found in 17.75% (n1⁄485) of the patients. Conclusions: The acetilconlinesterasa inhibitors as a group, are the treatment of choice among specialists in dementia in Mexico followed by Memantine. Rivastigmine is the most commonly used acetylcholinesterase inhibitor for the treatment of AD in Mexico. Poster Presentations: P2 P469 Figure 1. Distribution of patients with Alzheimer’s disease according to type ofmedication received as cognitive impairment treatment. AChel: Acetyl cholinesterase inhibitors. P2-300 DEMENTIA IN ASIA: REPORT OF THE WAVE 2 ASIA DEMENTIA EXPERT SURVEY Guk Hee Suh, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-Si, South Korea. Contact e-mail: suhgh@chol.com Background:Over 60 percent of the world population is living in Asia. An epidemic with a consequent explosion of the number of people with dementia will be unavoidable. The aims are to ascertain country-specific patterns of diagnosis, treatment and care of dementia and to investigate country-specific characteristics related to awareness of dementia with barriers and challenges in Asian countries. Methods: To find time trends, two surveys using the same questionnaire had been conducted in 2009 and 2012, All the same participants of 11 Asian countries (i.e., Korea, Japan, mainland China, Hong Kong SAR, Taiwan, Singapore, Philippines, Malaysia, Indonesia, Thailand, India) completed both surveys. The questionnaire consisted of 33 questions; participant demographics, awareness of AD and other dementia, characteristics of patients with memory problems, referral, diagnosis of MCI and dementia, diagnostic tools including the high-technology device, pharmacological treatment of MCI and dementia, current issues on AD, barriers and challenges in the treatment and care of dementia, and general health issues of one’s own country. Results: Dementia ranked last among 5 common diseases (i.e., cancer, heart disease, cerebrovascular disease, infectious disease) except Korea and Japan. Brain imaging studies like CT, MRI, SPECT, or PET are applied for more than 75 % of patients as a usual part of the diagnostic workup in most countries. In 2009, none out of 11 were going to adopt new criteria for clinical practice in their memory clinics because of invasiveness and too high cost. However, 7 respondents indicated that the new research diagnostic criteria may replace current criteria now or in near future and they will adopt new criteria for clinical practice. Cholinesterase inhibitors are prescribed in more than 90% of patients in 6 countries (i.e. Korea, Japan, Taiwan, Singapore, Philippines, Malaysia). In other countries, medications like memantine, huperzine, ginkgo biloba, vitamin E, and herb medicine are more frequently prescribed. Much more data remains. Conclusions: Dementia must be the public health priority. The cost of caring for people with dementia is likely to rise even faster than its prevalence. Every society must prepare to address the social and economic burden caused by an epidemic of dementia.